Domperidone cardiac warning
MIMS News, 2012
The MHRA has issued guidance regarding the risk of QT prolongation in patients treated with domperidone.
Patients should seek prompt medical attention if symptoms such as syncope or tachyarrhythmia appear during treatment | SCIENCE PHOTO LIBRARY
Two studies have shown that may increase the risk of serious ventricular arrhythmias or sudden cardiac death, particularly in patients older than 60 years or taking doses greater than 30mg daily.
Caution is required when treating patients with prolonged cardiac conduction intervals, significant electrolyte disturbances or underlying cardiac disease.
The lowest effective dose should be used and patients should seek prompt medical attention if symptoms such as syncope or tachyarrhythmia appear during treatment.
View rest of article at www.mims.co.uk «
Related articles
Below are some of our articles related to the article above:
